SCHEMBL4845404

SCHEMBL4845404

N#Cc1cc(C(F)(F)F)ccc1Nc1cc(F)ccc1[N+](=O)[O-]

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 0.49
AKR1C4 P17516 2/20 0.49
AKR1C3 P42330 2/20 0.49
AKR1C2 P52895 2/20 0.49
AKR1C1 Q04828 2/20 0.49
EPAS1 Q99814 1/20 0.46
MAPK1 P28482 5/20 0.44
MAPT P10636 5/20 0.43
HTT P42858 3/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
FBP1 P09467 1/20 0.40
TAS2R14 Q9NYV8 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
ATM Q13315 1/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 2/20 0.39
LMNA P02545 1/20 0.39
ALOX12 P18054 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4842658 0.92 EPAS1 (0.53) AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL4840809 0.87 MAPK1 (0.48) AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL4843827 0.85 AKR1C3 (0.54) AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL4846304 0.81 EPAS1 (0.55) AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL4836271 0.80 HTT (0.41) EPAS1MAPK1MAPTHTTMEN1
SCHEMBL4844419 0.79 MEN1 (0.39) MAPK1MAPTHTTMEN1KMT2A
SCHEMBL11381680 0.76 MAPT (0.43) AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL4841127 0.74 MAPK1 (0.44) MAPK1MAPTHTTMEN1KMT2A
SCHEMBL463657 0.73 VCAM1 (0.58) MAPK1MAPTMEN1KMT2ATDP1
SCHEMBL31672177 0.73 VCAM1 (0.58) MAPK1MAPTMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384934-B2 Piperazine substituted aryl benzodiazepines ELI LILLY AND COMPANY (US) 2008-06-10 US disclosed
US-7384934-B2 Piperazine substituted aryl benzodiazepines ELI LILLY AND COMPANY (US) 2008-06-10 US disclosed
EP-1546134-B1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES LILLY CO ELI (US) 2007-05-02 EP disclosed
US-20060084643-A1 Piperazine substituted aryl benzodiazepines ELI LILLY AND COMPANY 2006-04-20 US disclosed
EP-1546134-A1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES ELI LILLY AND COMPANY (US) 2005-06-29 EP disclosed
WO-2004014895-A1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES ELI LILLY AND COMPANY (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084643-A1 Piperazine substituted aryl benzodiazepines GABBR1, GABBR2, GABRA5 AKR1B1 953/4885AKR1C4 1388/4885AKR1C3 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.